Scarica l'app Stockscreener
2.72
4.56%
-0.13
Dopo l'orario di chiusura:
2.70
-0.02
-0.74%
Precedente Chiudi:
$2.85
Aprire:
$2.7199
Volume 24 ore:
46,320
Relative Volume:
3.67
Capitalizzazione di mercato:
$23.18M
Reddito:
-
Utile/perdita netta:
$-21.07M
Rapporto P/E:
-0.2745
EPS:
-9.9082
Flusso di cassa netto:
$-19.96M
1 W Prestazione:
-6.21%
1M Prestazione:
-8.42%
6M Prestazione:
-1.81%
1 anno Prestazione:
+17.75%
Intervallo 1D:
$2.70
$2.80
Intervallo di 1 settimana:
$2.70
$2.94
Portata 52W:
$2.05
$3.83
Lisata Therapeutics Inc Stock (LSTA) Company Profile
Nome
Lisata Therapeutics Inc
Settore
Industria
Telefono
908-229-2590
Indirizzo
110 ALLEN ROAD, BASKING RIDGE
Confronta LSTA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| LSTA | 2.72 | 23.18M | 0 | -21.07M | -19.96M | -9.9082 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Lisata Therapeutics Inc Borsa (LSTA) Ultime notizie
Lisata Therapeutics CEO discusses pancreatic cancer trial progress and new collaborationsICYMI - Proactive Investors USA
Lisata Therapeutics CEO David Mazzo on Q3 results; updates on key clinical trials and partnerships - Proactive Investors Australia
Earnings call: Lisata Therapeutics reports on Q3 progress and trials - Investing.com
Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q3 2024 Earnings Call Transcript - Insider Monkey
Lisata Therapeutics Inc (LSTA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Cost Management Success - GuruFocus.com
Lisata Therapeutics Inc (LSTA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Cost ... By GuruFocus - Investing.com Canada
Lisata Therapeutics Inc (LSTA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Cost ... - Yahoo Finance
Lisata Therapeutics Reports Q3 2024 Financial Results - TipRanks
Lisata Therapeutics Inc Reports Q3 2024 EPS of $0.59 and Net Los - GuruFocus.com
Lisata Therapeutics advances clinical trials in Q3 ahead of 'data-rich' 2025 - Proactive Investors USA
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
LSTALisata Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Lisata and ValoTx announce melanoma research collaboration - Investing.com
Lisata and ValoTx announce melanoma research collaboration By Investing.com - Investing.com UK
Lisata Therapeutics forms partnership for preclinical cancer immunotherapy study - Proactive Investors USA
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration - The Manila Times
Lisata, Valo Therapeutics Partner on Novel Melanoma Treatment Study | Key Research Collab | LSTA Stock News - StockTitan
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024 - The Manila Times
Lisata Therapeutics to Report Third Quarter 2024 Financial - GlobeNewswire
Lisata Therapeutics to Report Q3 2024 Results: Clinical-Stage Cancer Drug Updates | LSTA Stock News - StockTitan
Lisata Therapeutics partners with University of Cincinnati to investigate endometriosis therapyICYMI - Proactive Investors Australia
Lisata Therapeutics, Inc. (LSTA) Upgraded to Buy: Here's What You Should Know - MSN
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events - GlobeNewswire
Lisata Therapeutics, University of Cincinnati explore combination treatment for Endometriosis - Proactive Investors UK
Lisata announces preclinical research agreement to study certepetide with bevacizumab for endometriosis - BioWorld Online
Lisata Therapeutics Announces Sponsored Preclinical - GlobeNewswire
Lisata Therapeutics strikes research partnership to investigate new treatment for endometriosis - Proactive Investors USA
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis - GlobeNewswire
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events - The Manila Times
Lisata Therapeutics reiterates stock target, buy rating amid trial update - Investing.com India
Troy Wichterman Sells 611 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock - Defense World
Biolife Solutions exec sells over $77k in company stock - Investing.com India
Bilibili Inc. (NASDAQ:BILI) Short Interest Update - Defense World
BioLife Solutions, Inc. (NASDAQ:BLFS) Short Interest Down 7.1% in August - Defense World
Lisata Therapeutics reiterates stock target, buy rating amid trial update By Investing.com - Investing.com Canada
Market cap of Bilibili Inc ADR [BILI] reaches 4.87B – now what? - The DBT News
BLFS (Biolife Solutions Inc) may reap gains as insiders became active recently - Knox Daily
Daiwa Securities Group Inc. Has $71,000 Stock Position in Bilibili Inc. (NASDAQ:BILI) - Defense World
Short Interest in Bilibili Inc. (NASDAQ:BILI) Drops By 8.3% - MarketBeat
FDA Approves Ebglyss for Treatment of Moderate to Severe Atopic Dermatitis - Managed Healthcare Executive
BioLife Solutions, Inc. (NASDAQ:BLFS) Short Interest Update - MarketBeat
Lisata Therapeutics Announces First Patient Treated in the - GlobeNewswire
Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial - StockTitan
Lisata Therapeutics begins treating second cohort of patients in bile duct cancer trial - Proactive financial news
Lebrikizumab FDA Approved for Moderate to Severe Atopic Dermatitis in Adults and Children - The Dermatologist
Lilly Announces FDA Approval of Lebrikizumab-lbkz for Moderate to Severe Atopic Dermatitis - Patient Care Online
Ebglyss Approved for Moderate to Severe Atopic Dermatitis - Monthly Prescribing Reference
FDA Approves Lebrikizumab for Atopic Dermatitis - Medscape
Lilly gains FDA approval for lebrikizumab for atopic dermatitis - Seeking Alpha
FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis - Investors | Eli Lilly and Company
Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events - GlobeNewswire
Lisata Therapeutics Inc Azioni (LSTA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):